Oak Ridge Investments LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 5.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 143,973 shares of the company's stock after purchasing an additional 7,341 shares during the quarter. AstraZeneca comprises approximately 0.7% of Oak Ridge Investments LLC's portfolio, making the stock its 29th biggest holding. Oak Ridge Investments LLC's holdings in AstraZeneca were worth $9,433,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the business. Martin Investment Management LLC lifted its holdings in AstraZeneca by 2.8% during the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company's stock worth $22,571,000 after purchasing an additional 7,615 shares in the last quarter. Nordea Investment Management AB bought a new stake in shares of AstraZeneca during the fourth quarter valued at about $754,000. Integrated Advisors Network LLC lifted its holdings in shares of AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company's stock worth $3,398,000 after buying an additional 13,860 shares in the last quarter. Creative Planning boosted its position in shares of AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company's stock valued at $17,510,000 after acquiring an additional 16,692 shares during the period. Finally, Soros Fund Management LLC grew its stake in AstraZeneca by 8.2% during the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company's stock valued at $206,677,000 after acquiring an additional 201,233 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.
AstraZeneca Price Performance
Shares of NASDAQ AZN traded down $0.31 during mid-day trading on Friday, reaching $66.60. 5,419,360 shares of the company were exchanged, compared to its average volume of 4,140,949. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company's 50 day moving average price is $66.11 and its 200 day moving average price is $74.48. The stock has a market capitalization of $206.50 billion, a PE ratio of 31.87, a PEG ratio of 1.05 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company's revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 earnings per share. Sell-side analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several analysts have issued reports on AZN shares. UBS Group upgraded shares of AstraZeneca from a "sell" rating to a "neutral" rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a "sell" rating to a "hold" rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $89.75.
Read Our Latest Stock Analysis on AZN
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.